|Day's Range||6.75 - 7.02|
|52 Week Range||2.67 - 7.39|
|PE Ratio (TTM)||163.10|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||4.00|
Osiris Therapeutics Inc. has hired a new CEO — its fourth since February 2016. Linda Palczuk, 55, will start in the position July 10, replacing Interim CEO David A. Dresner. Columbia-based Osiris, which develops drugs and medical treatments using stem cells, was delisted from the NASDAQ composite earlier this year after repeatedly failing to file financial statements with the U.S. Securities and Exchange Commission.
COLUMBIA, Md., June 26, 2017-- Osiris Therapeutics, Inc. is pleased to announce that its Board of Directors has appointed Ms. Linda Palczuk, age 55, to serve as President and CEO, effective July 10, 2017. ...
COLUMBIA, Md., June 14, 2017-- Osiris Therapeutics, Inc., a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced ...